OBJECTIVE: To compare the efficacy and safety of Sacubitril valsartan sodium tablets and Benazepril hydrochloride tablets in the treatment of chronic heart failure with reduced ejection fraction

so as to explore effective medication regimens for clinical treatment. METHODS: Totally 102 chronic heart failure with reduced ejection fraction patients admitted into Changshu No. 2 People’s Hospital from Dec. 2018 to Dec. 2019 were extracted to be divided into the ARNI group and the ACEI group via the random number table and opaque envelope method

with 51 cases in each group. Patients in the ARNI group received Sacubitril valsartan sodium tablets

while the ACEI group was given Benazepril hydrochloride tablets. Clinical efficacy

cardiac function indicators [left ventricular posterior wall thickness（ LVPWD）

left ventricular ejection fraction（ LVEF）

left ventricular end-diastolic diameter（ LVEDD）

left ventricular global longitudinal strain（ GLS）

radial strain（ GRS） and circumferential strain（ GCS） during diastole]

myocardial injury markers [N-terminal precursor brain natriuretic peptide（ NT-ProBNP）

serum troponin I（ cTn I） ]

inflammatory mediators and myocardial fibrosis markers [soluble growth stimulating expression gene 2 protein（ s ST2）levels

interleukin（ IL）-1 and IL-6] before and after treatment

adverse drug reactions during medication in two groups were observed and compared. RESULTS: The total effective rate in the ARNI group was 90. 20%（ 46/51）

significantly higher than that in the ACEI group（ 74. 51%

38/51）

with statistically significant difference（ P <0. 05）. After treatment

the absolute values of LVEF

GLS and GCS of all patients were significantly higher than those before treatment

and LVPWD

LVEDD

NT-ProBNP

cTn Ⅰ

IL-1

IL-6 and s ST2 were significantly lower than those before treatment; meanwhile

the increase of LVEF in the ARNI group was greater

and the decrease of LVPWD

LVEDD

NT-proBNP

IL-1

IL-6

cTnⅠ and SST2 was greater

with statistically significant difference（ P< 0. 05）. After 12 months of follow-up

1 patient developed hypotension

1 patient developed cough

and 1 patient was readmitted to hospital

but no hyperkalemia or death was observed in the ARNI group. In the ACEI group

1 patient developed hypotension

1 patient developed cough

4 patients were readmitted to hospital

and 1 patient death

but no hyperkalemia was observed. CONCLUSIONS: Compared with Benazepril hydrochloride tablets

Sacubitril valsartan sodium tablets are more effective in improving heart function

inflammatory factors and myocardial injury markers in chronic heart failure with reduced ejection fraction patients

with better clinical efficacy and similar safety.